Salt Investments

Salt Bio is a clinical-stage biotechnology company focused on overcoming the primary limitations of current gene therapy delivery. The company is developing a proprietary platform designed to enable the repeat dosing of adeno-associated virus (AAV) gene therapies by managing the immune response to the viral vector. By utilizing specialized desensitization techniques, Salt Bio aims to expand the patient population eligible for gene therapy, including those with pre-existing immunity to AAV. Their technology seeks to transform gene therapy from a one-time treatment into a more flexible, redosable therapeutic modality for various genetic and rare diseases.